Article: In Silico and Laboratory Developability Assessment
Streamlining Drug Development with Integrated In Silico and Laboratory Developability Assessments
This new article from Coriolis Pharma highlights how early developability assessments can prevent late-stage failures. By integrating lab-based and in-silico analyses, Coriolis identifies risks early, optimizes formulations, and supports faster, more cost-effective drug development from discovery to market.
Late-stage failures in drug development often result from advancing molecules that are difficult to formulate or manufacture. Coriolis Pharma addresses this challenge by combining laboratory-based and in silico developability assessments to provide early insights into molecule characteristics and potential liabilities, optimize formulations, and mitigate risks. By streamlining decision-making processes and predicting stability and manufacturability issues early on, Coriolis helps developers reduce costs, accelerate timelines, and improve the likelihood of success from discovery to commercialization.
Evolving the Drug Development Playbook with Early-Stage Developability AssessmentsThe biopharmaceutical industry faces mounting pressure to accelerate the timeline for bringing new therapies to market. However, advancing molecules through development without proper scrutiny often leads to costly failures in later stages. A significant portion of these failures can be traced back to advancing candidates that ultimately prove difficult to formulate or manufacture at scale.
Given the immense financial and time investment required to develop new drugs, the importance of evaluating a molecule’s developability early in the process cannot be overstated. Developability assessments identify the inherent properties of a candidate that predict its potential to be developed into a safe, effective, and commercially viable drug. By conducting these assessments during early development, companies can proactively manage risks associated with stability, manufacturability, and scalability.
For biologic therapies, particularly monoclonal antibodies (mAbs) and related molecules, developability assessments focus on identifying critical biophysical properties. Stability, formulatability, and manufacturability are key considerations. Stability directly impacts the therapeutic’s long-term effectiveness and safety, while formulatability provides information on the degree of stability optimization achievable through formulation development. Manufacturability addresses compatibility with existing production technologies and processes.
Beyond merely identifying suitable candidates, early developability assessments streamline the entire drug development process. Computational modeling plays a vital role in this strategy by providing early insights without the need for extensive material testing. These models predict potential challenges, such as aggregation, chemical degradation, or viscosity issues, allowing developers to address risks before they become critical obstacles. This approach not only reduces the likelihood of late-stage failures but also significantly shortens development timelines and reduces costs.
Incorporating computational modeling into developability assessments allows for the evaluation of a broader range of molecules at the earliest stages, enabling the selection of candidates with the highest potential for success. This practice aligns with the growing industry trend toward quality by design, where every decision is driven by data to reduce risks and improve outcomes.
Ultimately, comprehensive developability assessments empower drug developers to make smarter, more informed decisions, increasing the likelihood of bringing effective therapies to market faster and with fewer setbacks.
